Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2016-08-17 Report Publication Anno…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Presentation of the second quarter 2016 results and Hexvix/Cysview update
Report Publication Announcement Classification · 95% confidence The document explicitly announces the 'Presentation of the second quarter 2016 results' and details the agenda, speakers, time, and location for this event. It also mentions hosting an audio webcast and conference call. This structure—announcing the presentation of periodic results and providing access details—is characteristic of an Earnings Release (ER) or, more specifically, an announcement leading up to the presentation of those results. Since the text focuses on the event schedule rather than containing the full financial report or the transcript itself, it aligns best with an Earnings Release announcement, which typically precedes the detailed report or call. However, because it is an announcement about a presentation of quarterly results, and the document is short and focuses on logistics, it could also be considered a Report Publication Announcement (RPA) if the actual results document is not included. Given the title explicitly mentions 'second quarter 2016 results' and the content details the presentation agenda, ER is a strong fit, but the 'MENU VS MEAL' rule suggests that if it's just an announcement of the presentation, RPA might be safer. Since it details the content of the presentation (Q2 results + Hexvix update), and the document is short (2778 chars), it is most likely an announcement about the release/presentation of the quarterly results, making RPA the most precise fit based on the provided definitions, as it is announcing the publication/event. Revisiting definitions: ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document announces the presentation of the results. RPA is 'Announcement regarding the timing, release, or publication of company reports'. Since this announces the presentation of the Q2 results, RPA is the most accurate classification for this logistical announcement.
2016-08-17 English
Disclosure of Large Shareholding
Major Shareholding Notification Classification · 99% confidence The document is titled 'Disclosure of Large Shareholding' and explicitly states that 'High Seas AS holding in Photocure ASA are now 3.230.000 shares and has now passed 15% threshold.' This content directly relates to a notification of a change in significant share ownership crossing a regulatory threshold (15%). This matches the definition for Major Shareholding Notification (MRQ). The document length is very short (299 chars), but the content is a direct notification, not an announcement *about* a notification, making MRQ the most specific fit over the general RNS fallback.
2016-08-16 English
Photocure ASA: CYSVIEW® GRANTED FDA APPROVAL OF NEW PREFILLED SYRINGE PRODUCT PACKAGING
Regulatory Filings Classification · 95% confidence The document is a short press release dated August 11, 2016, announcing that the FDA granted approval for new packaging for the Cysview product. It contains key highlights, product information, and company background, but it is not a comprehensive financial report (like 10-K or IR) or a transcript. It is an announcement of a specific regulatory event (FDA approval) and product update. Since it is a direct announcement of a significant event/update rather than a general regulatory filing fallback (RNS) or a specific financial report, it best fits the category of a general announcement or news release. Given the provided options, and since it is not a formal financial filing, a management change, or a dividend notice, it most closely resembles a general regulatory/company announcement. However, none of the categories perfectly capture a 'Press Release' announcing a regulatory approval. The closest fit among the specific categories that deal with product/regulatory milestones, but are not comprehensive reports, is difficult. Since it is a specific, non-financial, non-management, non-legal, non-dividend announcement, and it is not explicitly announcing the publication of a larger report (RPA), the most appropriate fallback for a specific, non-listed announcement is RNS (Regulatory Filings/Miscellaneous Announcements). If 'Press Release' were an option, that would be chosen. Given the constraints, RNS is the best fit for a specific, non-financial, non-periodic announcement.
2016-08-11 English
Photocure: New meta-analysis shows that BLC with Hexvix®/Cysview® significantly reduces rate of progression in bladder cancer
Regulatory Filings Classification · 95% confidence The document is a press release dated August 2, 2016, from Photocure ASA announcing the publication of a new systematic review and meta-analysis regarding the efficacy of BLC with Hexvix®/Cysview® in treating bladder cancer. It details clinical findings, quotes the CEO, and provides company background. This format—a news announcement summarizing recent developments, often including clinical trial results or publication notices—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/board change, and it is announcing a significant clinical finding/publication, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) as it is a material announcement. Given the content is a scientific/clinical update rather than core quarterly financial performance highlights, RNS is a strong candidate. However, many companies use ER for any major operational/clinical news release. Since it is a standalone announcement of a positive clinical finding, and not explicitly tied to a quarterly earnings report structure, RNS (Regulatory Filings/General Announcement) is the most appropriate general category for material, non-standard filings. Given the context of financial reporting databases, this type of announcement is often categorized broadly. I will select RNS as the best fit for a material, non-financial-statement-focused announcement.
2016-08-02 English
Photocure ASA: Save the date - Hexvix/Cysview update and second quarter 2016 results
Report Publication Announcement Classification · 99% confidence The document is a short announcement from Photocure ASA dated July 6, 2016, stating that they 'will present its second quarter report on Tuesday 23 August 2016' and providing an agenda for the event. It is not the actual Q2 report itself, nor is it a full transcript of a call. It is an announcement about the upcoming release of results and a presentation. According to Rule 2, if a document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA).
2016-07-06 English
Photocure announces resignation of Chief Operating Officer
Board/Management Information Classification · 100% confidence The document explicitly announces the resignation of the Chief Operating Officer (COO), Kathleen Deardorff, effective June 1, 2016. This type of announcement details changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and directly addresses a management change, fitting the MANG category perfectly.
2016-05-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.